Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | THRB | P10828 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16399632 | 0.90 | SMN1; SMN2 (0.61) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL24824540 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL19899477 | 0.85 | SMN1; SMN2 (0.57) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL1970981 | 0.83 | SMN1; SMN2 (0.67) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL16197142 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL12069921 | 0.83 | SMN1; SMN2 (0.55) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL10189882 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL25124309 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL315249 | 0.82 | SMN1; SMN2 (0.57) | SMN1; SMN2THRBGAAMAPTGPR119 | |
| SCHEMBL1968687 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2THRBGAAMAPTGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3022202-B1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | NOVARTIS AG (CH) | 2019-05-15 | — | — | EP | disclosed |
| US-10183025-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2019-01-22 | — | — | US | disclosed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| EP-3044221-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2018-02-21 | — | — | EP | disclosed |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2018-01-25 | — | — | US | disclosed |
| US-9763957-B2 | Autotaxin inhibitors | NOVARTIS AG (CH) | 2017-09-19 | — | — | US | disclosed |
| US-9611223-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2017-04-04 | — | — | US | disclosed |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH ROYAL CANCER HOSPITAL (THE) (GB) | 2016-08-04 | — | — | US | disclosed |
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | NOVARTIS AG (CH) | 2016-06-30 | — | — | US | disclosed |
| EP-3022202-A1 | AUTOTAXIN INHIBITORS COMPRISING A HETEROAROMATIC RING-BENZYL-AMIDE-CYCLE CORE | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
| EP-1701959-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | Pfizer Limited (GB) | 2006-09-20 | — | — | EP | disclosed |
| US-7084145-B2 | Triazole compounds useful in therapy | PFIZER INC. (US) | 2006-08-01 | — | — | US | disclosed |
| EP-1558598-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | Pfizer Limited (GB) | 2005-08-03 | — | — | EP | disclosed |
| WO-2005063754-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2005-07-14 | — | — | WO | disclosed |
| US-20050154024-A1 | Compounds useful in therapy | PFIZER INC | 2005-07-14 | — | — | US | disclosed |
| US-20040162278-A1 | Triazole compounds useful in therapy | PFIZER INC | 2004-08-19 | — | — | US | disclosed |
| WO-2004037809-A1 | TRIAZOLE COMPOUNDS FOR THE TREATMENT OF DYSMENORRHOEA | PFIZER LIMITED (GB) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184318-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | SMN1; SMN2 3331/4885THRB 2481/4885GAA 176/4885 |
| US-20040162278-A1 | Triazole compounds useful in therapy | AVPR2, AVPR1B, AVPR1A | SMN1; SMN2 4688/4885THRB 79/4885GAA 3565/4885 |
| US-20180021345-A1 | AUTOTAXIN INHIBITORS | ENPP2, SERPINB1, TFPI | SMN1; SMN2 3331/4885THRB 2481/4885GAA 176/4885 |
| US-20160221953-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP1 | SMN1; SMN2 3318/4885THRB 3148/4885GAA 2698/4885 |
| US-20050154024-A1 | Compounds useful in therapy | PTGER4, PTGER3, ALOX5 | SMN1; SMN2 3508/4885THRB 694/4885GAA 4652/4885 |
| US-10183025-B2 | Autotaxin inhibitors | ENPP2, SERPINB1, TFPI | SMN1; SMN2 3331/4885THRB 2481/4885GAA 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.